Xarelto Lawsuit Status

Xarelto

NastLaw is committed to providing the latest information on the Xarelto Lawsuit Status. We will provide updates as the litigation progresses to its second trial in Philadelphia, currently scheduled for January 2018.

If you are looking for information on how to file a Xarelto lawsuit, please call us toll free at 1-888-532-4719, or use our online form for a free, no obligation consultation.

Free Xarelto Lawsuit Consultation

Xarelto Lawsuit Status Update: February 7, 2018

$28M Verdict Overturn

On January 9, 2018, a Pennsylvania state judge overturned a previous $28M verdict over inadequate warnings about risks of internal bleeding from Xarelto.

The judge reversed the $28M settlement after a plaintiff’s physician had testified that additional warnings on the packaging would not have changed her decision to prescribe the drug.

The ruling voided the first case won by the plaintiffs, which is just one out of 1,400 cases pending as a part of Philadelphia County mass tort program, and over 18,500 more cases pending in federal court where they are consolidated in a Multidistrict Litigation at the U.S. District Court for the Eastern District of Louisiana.

NastLaw is diligently pursuing all Xarelto cases on behalf of our clients and will continue to post periodic updates about the litigation as new information becomes available.

Xarelto Lawsuit Status Update: December 6, 2017

First Trial Won by the Plaintiffs Resulted in a $28M Xarelto Lawsuit Settlement

On December 5, 2017, a Philadelphia jury ordered Bayer AG and Johnson & Johnson to pay $26 million in punitive and $1.8 million in compensatory damages to an Indiana couple over inadequate warnings about risks of internal bleeding from Xarelto.

The plaintiffs, Lynn Hartman and her husband, had filed a lawsuit against Johnson & Johnson and Bayer in 2015. Hartman was taking Xarelto for approximately one year, and in 2014 she was hospitalized with severe gastrointestinal bleeding, which she believed was caused by the blood thinner Xarelto.

This trial was the first case won by the plaintiffs, and is just one out of over 1,400 Xarelto cases pending in the Philadelphia court, and over 18,500 more cases are pending in federal court where they are consolidated in a Multidistrict Litigation at the U.S. District Court for the Eastern District of Louisiana.

Given the complexity of this litigation and the current trial schedule, there is a long road ahead. NastLaw is diligently pursuing all Xarelto cases on behalf of our clients and will continue to post periodic updates about the litigation as new information becomes available.

For more information on this litigation read this article by Reuters.

Xarelto Lawsuit Status Update: October 9, 2017

As previously reported, the first two cases tried in Federal Court resulted in jury verdicts in favor of the Defendants, Janssen and Bayer. The third Federal Court jury trial, Mingo v. Janssen Research & Development, et al, began on August 7, 2017 in Mississippi. This jury also found in favor of the Defendants. A fourth case, Henry v. Janssen Research & Development, et al, will be scheduled for trial in Federal Court in the near future.

All three trial cases involved different Plaintiffs with unique and distinct fact patterns. The verdicts achieved in the first three trials do not indicate with any certainty what the verdicts may be in the upcoming trials.

For cases filed in Pennsylvania State Court, Judge New scheduled the first jury trial, Hartman v. Janssen Research and Development, et al to begin on November 6, 2017. There are five additional cases scheduled for trial in Philadelphia but those trials will not begin until January 16, 2018. We anticipate that these trials will be completed in April 2018.

Individuals involved in the Xarelto litigation should be sure to preserve and maintain any documents in their possession related to the use of Xarelto. This includes all computer text files, spreadsheets, internet history files and preferences, social media files, and image files that relate to Xarelto or the claims made in the case. This also includes any paper records such as prescription purchases, insurance records, medical records and doctor visit records.

Given the complexity of this litigation and the current trial schedule, there is a long road ahead. NastLaw is diligently pursuing all Xarelto cases on behalf of our clients and will continue to post periodic updates about the litigation as new information becomes available.

Xarelto Lawsuit Status Update: June 21, 2017

Second Xarelto Bellwether Trial Win by the Defendants

On June 12, 2017, a New Orleans federal jury awarded a defense verdict to Bayer and Janssen in the second bellwether trial in 15,000-case litigation over severe health complications allegedly caused by their drug Xarelto.

This is the second time the drug manufacturers win in the multidistrict litigation.

There are two more trials scheduled in Federal Court in New Orleans, with the third one being set for August, 2017. The Philadelphia Xarelto trials are scheduled to begin in November 2017, after all four trials in New Orleans will be finalized.

At NastLaw, we will continue to update the Xarelto lawsuit status as the litigation advances.

Xarelto Lawsuit Status Update: June 7, 2017

Xarelto Bellwether Trials are Under Way

The Xarelto case is pursing rapidly. Unfortunately, the first Federal Court trial was won by the Defendants. There are three more trials scheduled in Federal Court in New Orleans. After these trials are over, the Xarelto trials will begin in Philadelphia County, Pennsylvania. The Philadelphia Xarelto trials are scheduled to begin in November 2017. It is very important that Plaintiffs win some of the trials that are scheduled as these cases are supposed to represent the average Xarelto case.

At NastLaw, we will continue to update the Xarelto lawsuit status as the litigation advances.

Xarelto Lawsuit Status Update: April 11, 2017

First Xarelto Trial Scheduled for April 24 in the Eastern District of Louisiana

In March, Judge Fallon, in the Eastern District of Louisiana, heard arguments from both parties about whether the first Xarelto case scheduled for trial had enough evidence that the plaintiff used Xarelto in order for the case to proceed to trial. Judge Fallon’s decision is expected within the next few weeks. Assuming there is enough evidence of proof of use of Xarelto, the first case will start on April 24 and last a few weeks.

In the next few weeks, Judge Fallon also is expected to make important ruling about what the experts for both sides are allowed to say at trial. These rulings will have great effect in future trials as orders for the first trial tend to stay in place for future trials.

In Philadelphia, the Xatelto cases are slightly behind cases in the Eastern District of Louisiana. However, in Philadelphia, there are 10 cases set for trial whereas there are only four cases set for trial in Louisiana. In Philadelphia, there are approximately 4 depositions each week. These depositions are proceeding at a rapid pace to prepare the 10 cases for trial.

At Nastlaw, we anticipate that there will be many Xarelto trials, with the defendants winning some and the Plaintiffs winning some. The results of these trials will be a large factor in whether the Defendants decide to resolve the litigation with a settlement or continue to try case after case. We will continue to keep you updated about the Xarelto litigation.

Xarelto Lawsuit Status Update: January 31, 2017

Reviewing Expert Testimony

The federal court Xarelto cases continue to move forward. Numerous expert reports have been exchanged by the parties and depositions of the experts have been taken.

At this point, Xarelto is in the legal briefing period, where both parties test the legal validity of each other’s expert reports. A hearing has been set in March of 2017 by the Honorable Eldon J. Fallon to hear argument about the legal validity of the Xarelto experts’ reports and depositions.

After that hearing, Judge Fallon will issue an opinion about the experts. The opinion will frame the Xarelto litigation for the parties. After the opinion is issued, if the experts are found to be sound, the cases are expected to proceed to trial.

In the Philadelphia County Xarelto litigation, the parties have picked 24 cases for trial work up and the depositions are ongoing. After the depositions are finished, a smaller pool of cases will be picked to be worked up further for trial.

At NastLaw, we are working vigorously to proceed in both Federal Court and in Philadelphia County to pursue our client’s claims.

Xarelto Lawsuit Status Update: January 3, 2017

14,000 Xarelto Lawsuits Pending, Four Bellwether Trials Set for Spring 2017

There are now almost 14,000 cases pending in the Xarelto MDL. US District Judge Eldon Fallon of the Eastern District of Louisiana will hear the first case in March 2017 from plaintiff Joseph Boudreaux. Mr. Boudreaux was hospitalized in early 2014 shortly after he started using Xarelto to help control his atrial fibrillation. He required multiple blood transfusions and has accused Janssen and Bayer of misrepresenting the safety profile of Xarelto.

Other Xarelto bellwether trials are scheduled for April 24 and May 30. More Xarelto lawsuits are being filed in courts around the country – learn more about Xarelto lawsuits here.

Xarelto Lawsuit Status Update: September 27, 2016

Deposition of Defendants’ Witnesses Almost Complete – Defendants Say They Will Not Settle Cases

The Xarelto case continues to move at a fast pace. The depositions of Defendants’ witnesses are almost completed and expert reports are due by mid November 2016. The parties will then take depositions of the experts.

The Defendants repeatedly say that the case will not settle, so the parties are expecting to try a lot of cases. In Federal Court, the first four trials have been delayed a little but there should be four cases tried to verdict by early Summer, 2017.

In Philadelphia, 10 trials are set for trial beginning at the end of Summer 2017, with cases being tried every two weeks for basically the rest of 2017.

Depositions of plaintiffs, medical providers and sales representatives continues in federal court and those depositions should be completed by October 3, 2016.

A very important date in the litigation is February 10, 2017, when the court will hear arguments about whether each parties experts should be allowed to testify. Basically, an expert is allowed to testify if the expert’s opinion is based on generally accepted science and the expert’s testimony will be helpful to the jury.

There are approximately 5,000 Xarelto cases filed in state and federal court. There are more cases filed every week. Fortunately, there are two very experienced judges managing the ligation. Lawyers from Nastlaw have devoted countless hours to working in the federal and state litigation. At Nastlaw, we firmly believe in working in both courts so our clients receive the best representation possible.

Xarelto Lawsuit Status Update: August 17, 2016

17 Xarelto Trials Scheduled for 2017

The Xarelto litigation is on track for 17 trials on 2017. This is an unusually fast pace for a large mass tort. In Xarelto, 17 cases will be tried in under three years from the date the first Xarelto lawsuit was filed.

The fast pace of Xarelto is due to a unique combination of factors:

  • First, the vast majority of the cases are being managed by two experienced and effective judges. In Federal Court, the Honorable Eldon Fallon is managing the litigation. In the past, Judge Fallon has managed several large MDLs, including Vioxx. In State Court, the Honorable Arnold New is managing the litigation. Judge New has managed numerous mass torts, including Yaz.
  • Second, Judge New and Judge Fallon have appointed lawyers to manage the litigation that have devoted their careers to mass torts. At NastLaw, Judge Fallon has appointed Dianne Nast to the Plaintiffs Steering Committee. Judge Fallon has also appointed Daniel Gallucci as a state liaison to the Federal Litigation. Judge New has appointed Daniel Gallucci as a co-liaison, which is the functional equivalent of co-lead counsel in the Xarelto Litigation.

This combination of experienced judges and experienced lawyers, hopefully, will result in injured plaintiffs getting their day in court with a speed that is virtually unheard of in mass tort litigation.

First Four Xarelto Trials Identified

On August 17, 2016, the the Honorable Eldon Fallon, who manages the Federal Xarelto litigation entered a case management order identifying the four cases that will be tried in federal court.

Judge Fallon identified the following cases for trial:

  • Trial 1: The matter of Joseph Boudreaux, Case No. 2:14-cv-02720, in the Eastern District of Louisiana.
  • Trial 2: The Matter of Joseph Orr, Jr., Case No. 2:15-cv-03708, in the Eastern District of Louisiana.
  • Trial 3: The Matter of Dora Mingo, Case No. 2:15-cv-03469, in Mississippi.
  • Trial 4: The Matter of James Henry, individually and as executor for the Estate of William Henry, Case No. 2:15-cv-00224, in Texas.

Xarelto Lawsuit Status Update: August 4, 2016

On August 4, 2016, the Honorable Eldon Fallon, the Federal Judge managing most of the Xarelto lawsuits in the United States held a hearing to discuss trial dates, coordinating the Federal litigation with the Xarelto litigation in Pennsylvania, and other issues.

Judge Fallon, in essence, ordered that the parties pick specific cases for trial by August 12, 2016. These cases will be tried in 2017.

Judge Fallon also requested the parties to work with the Xarelto litigation in Pennsylvania. There are over 800 Xarelto cases in Pennsylvania and the Honorable Arnold New manages those cases.

Judge New, in Pennsylvania, has directed the parties get 10 cases ready for trial starting in the Summer of 2017.

In total, Judge Fallon and Judge New manage over 95 percent of the Xarelto cases in the United States.

At Nastlaw, we litigate cases in front of both Judge Fallon and Judge New to make sure our clients receive the benefits of the work being done in both the Xarelto Federal litigation and the Xarelto state litigation.

Nastlaw will continue to update our website about the Xarelto lawsuits to keep you informed of important developments in the litigation.

Xarelto Lawsuit Status Update: July 2016

The Honorable Eldon Fallon, the Judge who is managing the Xarelto Federal litigation, has directed the parties to have cases ready for trial by February 6, 2017. Judge Fallon has set four trials. The first trial is set to take place in the Eastern district of Louisiana on February 6, 2017. Judge Fallon has scheduled three other trials to take place in March, April and May of 2017.

In order to have the cases prepared for trial; Judge Fallon has ordered the parties to take up to 50 depositions, to be completed by September 23, 2016. These deposition are of employees of the Defendants who were involved the development, marketing and sales of Xarelto.

Additionally, the Defendants have been ordered to produce approximately 50 million documents also relating to the development, marketing and sales of Xarelto.

While the Plaintiffs analyze the documents and take the deposition of Defendants’ witnesses, at the same time, plaintiffs who claim that they were injured by Xarelto and filed lawsuits, are being deposed by the Defendants.

By the end of September 2016, approximately 40 cases will be ready to be tried to a Jury.

Xarelto Lawsuit Status Update: February 2016

The Food and Drug Administration is investigating whether the results of the pivotal clinical trial used to approve Xarelto, known as the ROCKET AF trial, are still valid. This clinical trial compared the effectiveness of Xarelto to Warfarin and showed the two to be roughly equal in effectiveness. However, the trial results have been called into question because the device used to measure the amount of Warfarin in patients’ bodies has been recalled.

In the Xarelto litigation, we are also demanding documents and taking depositions on this issue. The validity of the ROCKET AF trial is a key question to whether Xarelto is safe and effective for use in patients with atrial fibrillation. We will continue to investigate this important safety issue.

Xarelto Lawsuit Information

Xarelto Lawsuits allege that the manufacturers of Xarelto:

  • Failed to fully investigate the safety risks of Xarelto
  • Failed to provide adequate warnings about the true safety risks associated with the use of Xarelto
  • Failed to adequately disclose the increased risk of severe bleeding while taking Xarelto
  • Failed to adequately disclose that there is no antidote to stop bleeding from Xarelto
  • Over promoted the drug to consumers and healthcare professionals, leading to an explosion in Xarelto sales and putting millions of users at risk

For more information, visit our website section on Xarelto Lawsuits.